Morpholino

MO1-mir26a

ID
ZDB-MRPHLNO-200609-1
Name
MO1-mir26a
Previous Names
None
Targets
Sequence
5' - AGCCTATCCTGGATTACTTGAAC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
View all 3 target locations
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-mir26a
Phenotype
Phenotype resulting from MO1-mir26a
No data available
Phenotype of all Fish created by or utilizing MO1-mir26a
Phenotype Fish Conditions Figures
whole organism smad1 expression increased amount, abnormal WT + MO1-mir26a control Fig 2 with image from Watterston et al., 2019
head myh11a expression increased amount, abnormal WT + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
head notch3 expression increased amount, abnormal WT + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
pharyngeal arch ventral region smad1 expression increased amount, abnormal WT + MO1-mir26a control Fig 2 with image from Watterston et al., 2019
head acta2 expression increased amount, abnormal WT + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
head pdgfrb expression increased amount, abnormal WT + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
ventral aorta smad1 expression increased amount, abnormal WT + MO1-mir26a control Fig 2 with image from Watterston et al., 2019
aortic arch smad1 expression increased amount, abnormal WT + MO1-mir26a control Fig 2 with image from Watterston et al., 2019
head smad1 expression increased amount, abnormal WT + MO1-mir26a control Fig 2 with imageFig. S4 from Watterston et al., 2019
head hemorrhagic, abnormal WT + MO1-mir26a control Fig 4 with imageFig. S4 from Watterston et al., 2019
pharyngeal arch ventral region myh11a expression increased amount, abnormal WT + MO1-mir26a control Fig. S5 from Watterston et al., 2019
head pdgfba expression increased amount, abnormal WT + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
pharyngeal arch ventral region acta2 expression increased amount, abnormal WT + MO1-mir26a control Fig. S5 from Watterston et al., 2019
whole organism ventralized, ameliorated WT + MO1-mir26a + MO1-smad1 control Fig 4 with image from Watterston et al., 2019
head hemorrhagic, ameliorated WT + MO1-mir26a + MO1-smad1 control Fig 4 with image from Watterston et al., 2019
ventral aorta endothelial cell decreased amount, ameliorated y7Tg + MO1-mir26a chemical treatment by environment: inhibitor Fig 6 with image from Watterston et al., 2019
ventral aorta vascular smooth muscle amount, ameliorated ca7Tg; ci5Tg + MO1-mir26a chemical treatment by environment: inhibitor Fig 6 with image from Watterston et al., 2019
ventral aorta length, ameliorated ca7Tg; ci5Tg + MO1-mir26a chemical treatment by environment: inhibitor Fig 6 with image from Watterston et al., 2019
aortic arch vascular smooth muscle amount, ameliorated ca7Tg; ci5Tg + MO1-mir26a chemical treatment by environment: inhibitor Fig 6 with image from Watterston et al., 2019
ventral aorta vascular smooth muscle decreased height, abnormal ca8Tg; mw29Tg + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
ventral aorta vascular smooth muscle increased amount, abnormal ca8Tg; mw29Tg + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
aortic arch EGFP expression increased amount, abnormal ca8Tg; mw29Tg + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
aortic arch vascular smooth muscle increased amount, abnormal ca8Tg; mw29Tg + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
aortic arch vascular smooth muscle decreased height, abnormal ca8Tg; mw29Tg + MO1-mir26a control Fig 5 with image from Watterston et al., 2019
Citations